Moderna stock has surged nearly 600% this year on a cancer vaccine trial result that almost no one outside the trial has ...

Moderna, Inc. was added back to the Nasdaq-100 index and earlier announced that former manufacturing leader Juan Andres would ...

Moderna’s updated modelling now points to a slightly higher fair value estimate, with the figure moving from US$119.56 to ...

Moderna Inc MRNA shares are rising Friday to a fresh 52-week high. The stock enters the Nasdaq-100 Index. Here’s what you should know. Moderna stock is at critical resistance. Why is MRNA stock ...

A coveted Presidential Symposium slot at Europe's top oncology congress just sent Moderna shares flying 9%, but the actual Phase 3 melanoma data remains unseen. Here is why the scheduling alone is ...

Moderna (MRNA) stock surged 14% after reports of a new NIH cancer research initiative and encouraging trial data with Merck.

One reason that analysts and doctors want to see the data is to better understand how well the personalized treatment works.

Following last month's super rally, a growing number of analysts are now calling for caution.

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent ...

CAMBRIDGE, Mass., April 21, 2026 (Newswire.com) - Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the ...